Brief: Alkermes Awarded Innovation Passport Designation By UK For Treatment Of Mucosal Melanoma

Alkermes

17/01/2023 12:13

Jan 17 (Reuters) - Alkermes Plc  ALKS.O :
    * ALKERMES AWARDED INNOVATION PASSPORT DESIGNATION BY THE
MHRA
(UK) FOR NEMVALEUKIN ALFA FOR THE TREATMENT OF MUCOSAL MELANOMA
    * ALKERMES AWARDED INNOVATION PASSPORT DESIGNATION BY THE
MHRA
(UK) FOR NEMVALEUKIN ALFA FOR THE TREATMENT OF MUCOSAL MELANOMA

Source text for Eikon:  ID:nPn7YXq9Ya 
Further company coverage:  ALKS.O 
 ((Reuters.Briefs@thomsonreuters.com;))